Imaging cortical dopamine D1 receptors using [ 11C]NNC112 and ketanserin blockade of the 5-HT2A receptors

Journal of Cerebral Blood Flow and Metabolism

Volumn 30, Issue 5, 2010, Pages 985-993

  Catafau, Ana M ^a   Searle, Graham E ^b   Bullich, Santiago ^c   Gunn, Roger N ^b,d,e   Rabiner, Eugenii A ^b,e   Herance, Raul ^c   Radua, Joaquim ^c,f   Farre, Magi ^g   Laruelle, Marc ^b,e  

^a GLAXOSMITHKLINE   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Institut d'Alta Tecnologia   (Spain)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

11C NNC112; D1 receptors; Ketanserin; PET; Selectivity

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE C 11; DOPAMINE 1 RECEPTOR; KETANSERIN; RADIOPHARMACEUTICAL AGENT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN CORTEX; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; LIMBIC SYSTEM; MALE; MOLECULAR IMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; ANIMALS; BENZAZEPINES; BENZOFURANS; BRAIN; CARBON RADIOISOTOPES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KETANSERIN; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D1; STAINING AND LABELING; YOUNG ADULT;

EID: 77952011907     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2009.269     Document Type: Article

References (36)

1. Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M (2000) Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20:225-43
2. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-19
3. Andersen PH (1988) Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113-20
4. Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (1992) NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol 219:45-52
5. Catafau AM, Danus M, Bullich S, Llop J, Perich J, Cunningham VJ, Plaza P, Penengo MM, Eersels JL, Squassante L, Ros D, Barbanoj M (2006 a) Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: part 1-pseudoequilibrium interval and quantification methods. J Nucl Med 47:919-28
6. Catafau AM, Danus M, Bullich S, Nucci G, Llop J, Abanades S, Cunningham VJ, Eersels JL, Pavia J, Farre M (2006 b) Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: part 2-ketanserin displacement. J Nucl Med 47:929-37
7. Distler A (1990) Clinical aspects during therapy with the serotonin antagonist ketanserin. Clin Physiol Biochem 8:64-80
8. Duffy RA, Hunt MA, Wamsley JK, McQuade RD (2000) In vivo autoradiography of [3H]SCH 39166 in rat brain: selective displacement by D1/D5 antagonists. J Chem Neuroanat 19:41-6
9. Eastwood SL, Burnet PW, Gittins R, Baker K, Harrison PJ (2001) Expression of serotonin 5-HT (2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse 42:104-14
10. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M (2007) In vivo DA D1 receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9:117-25
11. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS (1997) Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, DC: American Psychiatric Press Inc.
12. Friston KJ, Frith CD, Liddle PF, Frackowiak RS (1991) Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 11:690-9
13. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279-87
14. Guo N, Hwang DR, Lo ES, Huang YY, Laruelle M, Abi-Dargham A (2003) Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 28:1703-11
15. Israilova M, Suzuki F, Tanaka T, Nagatomo T, Taniguchi T, Muramatsu I (2002) Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology 65:69-73
16. Joris J, Banache M, Bonnet F, Sessler DI, Lamy M (1993) Clonidine and ketanserin both are effective treatment for postanesthetic shivering. Anesthesiology 79:532-9
17. Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D (1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761-7 (Pubitemid 34465049)
18. Kassiou M, Loc'h C, Bottlaender M, Mardon K, Ottaviani M, Coulon C, Katsifis A, Maziere B (2002) (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nucl Med Biol 29:295-302
19. Kassiou M, Mardon K, Mattner F, Katsifis A, Dikic B (2001) Pharmacological evaluation of (+)-2-[123I]A-69024: a radioligand for in vivo studies of dopamine D1 receptors. Life Sci 69:669-775
20. Kassiou M, Scheffel U, Ravert HT, Mathews WB, Musachio JL, Lambrecht RM, Dannals RF (1995 a) [11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. Nucl Med Biol 22:221-6
21. Kassiou M, Scheffel UA, Musachio JL, Stathis M, Dannals RF (1995 b) [3H]A-69024: a non-benzazepine ligand for in vitro and in vivo studies of dopamine D1 receptors. Life Sci 57:367-72
22. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-8
23. List SJ, Seeman P (1981) Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions. Proc Natl Acad Sci USA 78:2620-4
24. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang YY, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23:285-300
25. Mcbride WJ, Chernet E, Russell RN, Chamberlain JK, Lumeng L, Li TK (1997) Regional CNS densities of serotonin and dopamine receptors in high alcoholdrinking (HAD) and low alcohol-drinking (LAD) rats. Alcohol 14:603-9
26. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A (2005) Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162:2352-9
27. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-6
28. Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231-49 (Pubitemid 16241112)
29. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21:123-39 (Pubitemid 17076867)
30. Pinborg LH, Adams KH, Svarer C, Holm S, Hasselbalch SG, Haugbøl S, Madsen J, Knudsen GM (2003) Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab 23:985-96
31. Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, Hermanne JP, Guillaume M, Cantineau R, Comar D et al (1995) Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab 15:787-97
32. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, Abi-Dargham A (2007) [11C] NNC 112 selectivity for dopamine D1 and serotonin 5HT2A receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27:1733-41
33. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350:614-9 (Pubitemid 21912283)
34. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440-66
35. Travis MJ, Visvikis D, Erlandsson K, Mulligan RS, Matthiasson P, Waddington W, Costa DC, Pilowsky LS, Ell PJ, Kerwin RW (2000) Displacement of the selective 5HT2A radioligand 123-5-I-R91150 by unlabelled ketanserin. Schizophr Res 41:253
36. Tsukada H, Nishiyama S, Fukumoto D, Sato K, Kakiuchi T, Domino EF (2005) Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 30:1861-9